Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial in patients with metastatic, hormone refractory prostate cancer (HRPC). More than 400 patient-specific GVAX-induced antibody responses were identified in the sera of the treated patients by three different biochemical techniques confirming, as previously reported, that GVAX treatment results in a broad, multi-antigen immune response. An ongoing analysis of these GVAX-induced antibody responses has shown that at least two of the antibody responses are associated with patient survival, an association that is independent of the dose and number of treatments administered. These data will be presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the American Society of Clinical Oncology's Genitourinary Cancer Symposium being held in San Francisco, California.

Cell Genesys has previously reported the results of two multicenter Phase 2 trials of GVAX immunotherapy for prostate cancer in metastatic HRPC. The second of these two trials enrolled 80 patients. The serum of 65 patients (the total number for whom adequate sera were available) were examined to determine each patient's immune response to two specific antigens, HLA-A24 and FLJ14668, following GVAX treatment. Thirty-four of 65 patients demonstrated an FLJ14668-specific antibody immune response. These 34 patients had a median survival of 43 months, compared to a median survival of 21 months achieved by the patients who did not generate anti-FLJ14668 antibodies (p=0.002). Twenty-t
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... WASHINGTON, Oct. 8 As Congress wraps up work ... of Transplantation,s (AST) Public Policy Committee arrived on Capitol ... health care provision that would ensure kidney transplant recipients ... The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients ...
... Adnavance Technologies Inc., a developer of direct detection ... Randy White, Ph.D. chief executive officer, will present initial ... clinical samples during company presentations at the following conferences: ... at 10:00 a.m. Eastern Time at the Walter E. ...
Cached Medicine Technology:AST on Capitol Hill to Promote Transplant Drug Extension Provision With Senate as Part of Health Care Reform 2Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference 2
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... thought to be cured by immediate and aggressive drug treatment ... AIDS-causing virus in her bloodstream, disappointed federal officials announced Thursday ... remained virus-free even though she stopped taking HIV medications when ... would open the door to a functional cure for all ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... Datalogic brings a new and innovative ... wide. With their new Gryphon GD4400 and ... the devastating MRSA, which claimed 5,500 lives, becomes more ... 2D and the Gryphon GM4400-HC 2D readers can scan ... read barcodes off of troublesome LCD monitors, smartphones, and ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... County residents will have the opportunity to witness a special, ... traditional lighting of the Saugatuck River Bridge at dusk. Those ... the door, will enjoy cuisine and drink from some of ... chance to participate in a silent auction that includes items ...
... VIEW, Calif., July 7 ... has closed its acquisition of the Managed Security Services ... VeriSign is the trusted provider of Internet infrastructure services ... strengthens its leadership position as a global, pure-play security ...
... , MORTON GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... a provider of other natural and organic dairy products, invites you ... throws out the first pitch before the Chicago Cubs take on ... , At this official "Lifeway Day with the Cubs," the local ...
... July 7 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and supplier of pharmaceutical,products and medical nutrients addressing a ... has commenced the full implementation of the,new rural cooperative ... Since the beginning of April, Biostar has deployed ...
... Web reports by states and municipalities , TUESDAY, July ... the United States get mixed marks for their use of ... outbreak, a new study shows. , After the U.S. government ... state health departments posted some information about the H1N1 outbreak ...
... the director of Developmental Care and Follow-up at Texas Children,s ... Medicine , has been appointed chair of the American Academy ... assumed the role on July 1st and will oversee the ... succeed Ann Stark, M.D., FAAP, chief of Neonatology at Texas ...
Cached Medicine News:Health News:Al's Angels' 'Angels in July' Saugatuck River Bridge Lighting to Benefit Children in Need 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 3Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 4Health News:Giant Bugs Invade Wrigley Field 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 3Health News:Mixed Marks for Swine Flu Updates 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 3
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
... a new level of immunodiagnostic productivity. Optimal ... any laboratory automation system. No-pause loading of ... the only immunoassay system with this capability. ... runs without any additional setup. Continuous sample ...
... and medium volume laboratories, as well as ... the speed, simplicity and flexibility needed to ... powerful, the Elecsys 1010 system enables operators ... to routine testing without sacrificing ease of ...
Medicine Products: